课题基金 / 基金详情

SUSTAINED RELEASE CYCLOSPORIN FOR TREATMENT OF UVEITIS

SUSTAINED RELEASE CYCLOSPORIN FOR TREATMENT OF UVEITIS
缓释环孢素治疗葡萄膜炎
批准号:
2421826
负责人:
PAUL ASHTON
金额:
$9.22万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-09-30 至 1998-06-30

项目摘要

项目成果

PAUL ASHTON的其他基金

相似基金

相关文献

中文摘要
翻译
描述(改编自研究者摘要):宽,长
英文摘要
DESCRIPTION (Adapted from the Investigator's Abstract): The broad, long- term goal of this research is to reduce or eliminate the blindness due to uveitis. A promising device for the sustained intraocular release of cyclosporine A (CsA) is being investigated in academia. This device is similar to the Vitrasert, a 6-8 month sustained-release ganciclovir device, developed by the same investigators that requires a 5-6 mm pars plana incision for insertion. As part of SBIR EY-43-11316, they have improved the Vitrasert so that it can be inserted through a 3-4 mm incision. The purpose of this work described in this proposal is to perform preliminary work to adapt this Vitrasert 2 technology so as to prepare 5 year CsA devices implantable through small incisions. The specific aims of this proposal therefore are to: 1. Develop and produce high and low dose "Vitrasert 2"; 2. Validate the sterilization procedures for these; devices. 3. Test release rates of the devices in vivo. Successful completion of this Phase 1 study will be followed by large scale preparation of these systems, submission of an Investigational New Drug Exemption and initiation of clinical trials. This work will form the basis of our Phase 2 SBIR proposal. Control delivery Systems (CDS) has experience in all aspects of the drug approval process. Their first product, the Vitrasert, was licensed to Chiron Vision. Royalties from the sale of this device allow them to commit internal CDS funds to Phase 3 of this work. Approximately 30,000 people in the United States are blind because of uveitis. The successful completion of this work will result in a product which will reduce that number in the future. This product will have orphan drug status and a "fast track" regulatory pathway which will help to ensure its commercial viability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SUSTAINED RELEASE CYCLOSPORINE FOR TREATMENT OF UVEITIS
  • 批准号:
    2870333
  • 项目类别:
  • 资助金额:
    $22.63万
  • 财政年份:
    1999
  • 负责人:
    PAUL ASHTON
  • 依托单位:
INTRAVITREAL FLUOCINOLONE IMPLANT MACULAR DEGENERATION
  • 批准号:
    6015306
  • 项目类别:
  • 资助金额:
    $9.89万
  • 财政年份:
    1999
  • 负责人:
    PAUL ASHTON
  • 依托单位:
SUSTAINED RELEASE CYCLOSPORINE FOR TREATMENT OF UVEITIS
  • 批准号:
    6179871
  • 项目类别:
  • 资助金额:
    $27.24万
  • 财政年份:
    1999
  • 负责人:
    PAUL ASHTON
  • 依托单位:
BIOERODIBLE INTRAVITREAL DRUG DELIVERY SYSTEMS
  • 批准号:
    2165289
  • 项目类别:
  • 资助金额:
    $12.81万
  • 财政年份:
    1995
  • 负责人:
    PAUL ASHTON
  • 依托单位:
海外基金